Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro.
Csernus. V V; Schally. A V AV; Groot. K K
Key Findings
- GHRH antagonists (e.g., MZ-5-156) at 100‑200 nM blocked GHRH‑ and VIP‑induced cAMP release in several human cancer cell lines.
- cAMP is a key second messenger that promotes cell growth; lowering it may hinder tumor growth.
- The inhibition was observed across breast, prostate, and pancreatic cancer cells, suggesting a broad anti‑cancer potential for GHRH blockers.
Practical Outcomes
- For biohackers using sermorelin or other GHRH agonists, the data suggest a theoretical caution: chronic GHRH stimulation could elevate cAMP in cells that express GHRH receptors, potentially supporting tumor growth. Until more human data are available, consider limiting long‑term high‑dose use, especially if you have personal or family cancer risk, and monitor any unusual health changes.
Summary
The study shows that drugs that block the natural hormone GHRH can stop cancer cells from making a signaling molecule (cAMP) that helps them grow. While sermorelin is a GHRH‑like drug that boosts growth hormone, this research hints that stimulating the GHRH pathway might, in theory, support cancer cell activity, so users should be aware of a possible risk, especially if they have a history of cancer.
Abstract
Antagonistic analogs of growth hormone-releasing hormone (GHRH) inhibit growth of various human cancers both in vivo and in vitro. GHRH, vasoactive intestinal peptide (VIP), and pituitary adenylate cyclase-activating peptide stimulate cyclic AMP (cAMP) release from various human cancer cell lines in vitro. Thus, in the present study, we investigated the effects of antagonistic analogs of GHRH on the GHRH- and VIP-induced cAMP release from cultured human cancer cells in a superfusion system. Various human cancer cell lines were exposed to human GHRH(1-29)NH2 (2-20 nM) or VIP (0.1-5 nM) repeatedly for 12 min or continuously for 96 min. GHRH antagonist MZ-5-156 at 100 to 200 nM concentration inhibited the GHRH- or VIP-induced cAMP release from mammary (MDA-MB-468), prostatic (PC-3), and pancreatic (SW-1990 and CAPAN-2) cancer cells. These results show that antagonistic analogs of GHRH suppress the stimulatory effects of GHRH and VIP on the cAMP production of various cancer cells. Because cAMP is a potent second messenger controlling many intracellular functions, including the stimulation of cell growth, an inhibition of autocrine/paracrine action of GHRH by the GHRH antagonists may provide the basis for the development of new methods for cancer treatment.
Study Information
pubmed
1999
10.1016/s0196-9781(99)00071-6